{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:21:29Z","timestamp":1762863689927,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":1894,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1002\/rth2.12035","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T09:49:05Z","timestamp":1502358545000},"page":"296-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neurosurgery in a patient at peak levels of rivaroxaban: taking into account all factors"],"prefix":"10.1016","volume":"1","author":[{"given":"Jan","family":"De Vlieger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Dietvorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rik","family":"Demaerel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Nuttin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vanassche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12035_bb0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12035_bb0015","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12035_bb0020","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12035_bb0025","first-page":"189","article-title":"Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?","volume":"111","author":"Dickneite","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12035_bb0030","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.1097\/01.brs.0000202760.30257.88","article-title":"Spinal chronic subdural hematoma in association with anticoagulant therapy: a case report and literature review","volume":"31","author":"Jimbo","year":"2006","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1002\/rth2.12035_bb0035","doi-asserted-by":"crossref","first-page":"E547","DOI":"10.1097\/00007632-200112010-00022","article-title":"Acute nontraumatic spinal subdural hematomas in three patients","volume":"26","author":"Morandi","year":"2001","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1002\/rth2.12035_bb0040","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3171\/spi.2005.2.5.0612","article-title":"Spontaneous spinal subdural hematoma associated with low\u2010molecular\u2010weight heparin. Case report","volume":"2","author":"Cha","year":"2005","journal-title":"J Neurosurg Spine"},{"key":"10.1002\/rth2.12035_bb0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2016.05.020","article-title":"Intracranial subdural hematomas with elevated rivaroxaban concentration and subsequently detected spinal subdural hematoma: a case report","volume":"143","author":"Yamaguchi","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12035_bb0050","first-page":"275380","article-title":"Rivaroxaban\u2010induced nontraumatic spinal subdural hematoma: an uncommon yet life\u2010threatening complication","volume":"2015","author":"Zaarour","year":"2015","journal-title":"Case Rep Hematol"},{"issue":"Suppl 1","key":"10.1002\/rth2.12035_bb0055","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00586-015-4160-2","article-title":"Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management","volume":"25","author":"Dargazanli","year":"2016","journal-title":"Eur Spine J"},{"key":"10.1002\/rth2.12035_bb0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.12659\/AJCR.893320","article-title":"Non\u2010traumatic spontaneous spinal subdural hematoma in a patient with non\u2010valvular atrial fibrillation during treatment with rivaroxaban","volume":"16","author":"Castillo","year":"2015","journal-title":"Am J Case Rep"},{"key":"10.1002\/rth2.12035_bb0065","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/ALN.0000000000000863","article-title":"Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model","volume":"123","author":"Honickel","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1002\/rth2.12035_bb0070","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo\u2010controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1002\/rth2.12035_bb0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","article-title":"Edoxaban effects on bleeding following punch biopsy and reversal by a 4\u2010factor prothrombin complex concentrate","volume":"131","author":"Zahir","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/rth2.12035_bb0080","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non\u2010vitamin K antagonist anticoagulants in patients with non\u2010valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frth2.12035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922021744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922021744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/rth2.12035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:16:24Z","timestamp":1762863384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922021744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S2475037922021744"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12035","relation":{},"ISSN":["2475-0379"],"issn-type":[{"type":"print","value":"2475-0379"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurosurgery in a patient at peak levels of rivaroxaban: taking into account all factors","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}